Viewray (VRAY) Receives News Sentiment Score of 0.14
Media coverage about Viewray (NASDAQ:VRAY) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Viewray earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.3016111252667 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Viewray (VRAY) traded up $0.07 on Monday, reaching $8.57. 549,400 shares of the company traded hands, compared to its average volume of 724,872. Viewray has a 12-month low of $3.01 and a 12-month high of $10.39. The company has a debt-to-equity ratio of -1.67, a quick ratio of 1.20 and a current ratio of 1.59.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Monday, November 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million for the quarter, compared to analysts’ expectations of $18.63 million. The business’s revenue for the quarter was up 2950.0% compared to the same quarter last year. analysts expect that Viewray will post -0.93 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/viewray-vray-receives-news-sentiment-score-of-0-14/1771503.html.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.